Guerbet : Change in General Management

Core Viewpoint - Guerbet has appointed Mr. Jérôme Estampes as interim Chief Executive Officer, succeeding Mr. David Hale, who is leaving the company to pursue new projects [2][3]. Company Management Changes - Mr. Jérôme Estampes has been with Guerbet since 2019 as Chief Administrative and Financial Officer, where he has developed a strong understanding of the company's financial, operational, and commercial challenges [3]. - The Board of Directors has expressed gratitude to Mr. David Hale for his contributions since joining in February 2018, first as Chief Commercial Officer and then as CEO from January 1, 2020 [2][4]. Transition and Future Leadership - The Board supports Mr. Estampes and he will have the assistance of Guerbet's Executive Committee to ensure a smooth transition and to continue implementing transformation measures and the commercial strategy [4]. - The Nominations and Remuneration Committee has initiated the recruitment process for a permanent Chief Executive Officer [4]. Company Overview - Guerbet is a global leader in medical imaging, focusing on improving patient care through innovation, with nearly a century of expertise [6]. - The company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging [6]. - Guerbet invests 10% of its annual revenue in research and development and reported €786 million in revenue in 2023 [6].